ArticleScientific reports2025
Cyanocobalamin (vitamin B12) ameliorates lipopolysaccharide-induced systemic and lung inflammation in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering the antioxidant and immunomodulatory properties of vitamin B12, this study aimed to evaluate the effects of cyanocobalamin (vitamin B12) on systemic and lung injury markers induced by lipopolysaccharide (LPS). Forty male Wistar rats were randomly assigned to five groups: Control; LPS (1 mg/kg, intraperitoneal injection on day 3 and from days 8 to 16); and LPS treated with cyanocobalamin at doses of 0.25, 0.5, and 1 mg/kg. Cyanocobalamin was administered orally from days 1 to 16. Finally, blood and lung tissue samples were collected to evaluate systemic and lung injury markers. Total white blood cell (WBC), neutrophil, eosinophil, and monocyte counts, as well as serum interleukin-6 (IL-6) levels, were elevated in LPS group compared to control animals. Treatment with cyanocobalamin at all doses reduced total WBC, neutrophil, and lymphocyte counts relative to the LPS group, except for total WBC at the 0.5 mg/kg dose. LPS induced upregulation of nitric oxide (NO), IL-6, tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), malondialdehyde (MDA), and the expression of Bax, p53, and the Bax/Bcl-2 ratio, along with histopathological injury. Conversely, it downregulated Bcl-2 expression, total thiol content, and catalase (CAT) and superoxide dismutase (SOD) activities in lung tissue compared to controls. Cyanocobalamin dose-dependently ameliorated LPS-induced lung alterations, including IL-6, TNF-α, MDA, thiol content, Bax, p53, Bax/Bcl-2 ratio expression, CAT activity, and injury score. These findings suggest that a synthetic form of vitamin B12, cyanocobalamin, ameliorates LPS-induced leukocytosis, lung inflammation, apoptosis, and oxidative stress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.